Clearmind Medicine Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder
Vancouver, Canada – Clearmind Medicine Inc., a clinical-stage biotech company specializing in the discovery and development of novel psychedelic-derived therapeutics, announced on March 18, 2025, the commencement of a Phase I/IIa clinical trial for its innovative treatment, CMND-100, in patients dealing with Alcohol Use Disorder (AUD). This study marks the first clinical application of Clearmind’s proprietary CMND-100 platform, signifying a crucial step forward in the company’s mission to provide groundbreaking solutions for addictions, weight loss, and mental health disorders.
About CMND-100
CMND-100 is a psychedelic-derived therapeutic developed by Clearmind. This treatment is designed to target the underlying mechanisms of various health conditions, including addictions, mental health disorders, and weight loss. The exact mechanism of action for CMND-100 in AUD is yet to be fully understood, but it is believed that it may help restore normal functioning in the brain circuitry affected by alcohol use.
The Clinical Trial
The Phase I/IIa clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100 in AUD patients. The trial will enroll approximately 40 participants, who will be randomly assigned to receive either CMND-100 or a placebo. The primary outcome measures will include safety, tolerability, and the change in alcohol consumption from baseline. Secondary outcome measures will include neuropsychological assessments and changes in biomarkers related to alcohol metabolism.
Impact on Individuals
For individuals struggling with alcohol use disorder, this clinical trial could potentially lead to a new, effective treatment option. Alcohol use disorder is a chronic and often relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. Current treatment methods include behavioral therapies, medications, and mutual support groups, but they often have limited success rates. The potential introduction of psychedelic-derived therapeutics like CMND-100 could offer a new approach to addressing the underlying causes of alcohol use disorder and improving treatment outcomes.
Impact on the World
If successful, the clinical trial for CMND-100 has the potential to revolutionize the way we approach alcohol use disorder and other health conditions. Alcohol use disorder affects millions of people worldwide, and current treatments have limited success rates. The development of effective and innovative treatments like CMND-100 could significantly reduce the burden on healthcare systems and improve the quality of life for those struggling with addiction. Furthermore, the success of this clinical trial could pave the way for further research into the potential of psychedelic-derived therapeutics for other conditions, such as mental health disorders and weight loss.
Conclusion
Clearmind Medicine’s initiation of the Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder marks a significant milestone in the company’s mission to develop innovative solutions for various health conditions. The potential introduction of psychedelic-derived therapeutics like CMND-100 could offer a new approach to addressing the underlying causes of alcohol use disorder and improving treatment outcomes. The success of this clinical trial could have far-reaching implications, potentially revolutionizing the way we approach addiction and other health conditions. As the trial progresses, we will continue to closely monitor the developments and share updates as they become available.
- Clearmind Medicine initiates Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder
- First clinical application of Clearmind’s proprietary CMND-100 platform
- Potential new approach to addressing underlying causes of alcohol use disorder
- Significant milestone in Clearmind’s mission to provide innovative solutions for addictions, weight loss, and mental health disorders
